Louise Chen
Stock Analyst at Scotiabank
(3.42)
# 993
Out of 5,112 analysts
300
Total ratings
46.67%
Success rate
4.59%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Initiates: Sector Outperform | $35 | $30.32 | +15.44% | 4 | Dec 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $45 → $53 | $53.33 | -0.62% | 1 | Dec 4, 2025 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $100.69 | +19.18% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $748.71 | +2.84% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $20.34 | +293.31% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $3.08 | +192.21% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $21.15 | -33.81% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $2.25 | +433.33% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $20.07 | +174.04% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $74.59 | -26.26% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $2.67 | +461.80% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $96.24 | -48.05% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.68 | +164.08% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $37.90 | -55.15% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $72.14 | -2.96% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $18.55 | +169.54% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $9.82 | +205.50% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $17.18 | +220.14% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.29 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $47.61 | +236.06% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $43.71 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $222.82 | +7.71% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $25.04 | +79.71% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $208.31 | +3.21% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.10 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $21.79 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,056.88 | -16.26% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.18 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.18 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.60 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.72 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $220.35 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.70 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.55 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.80 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.88 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.63 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.23 | +1,912.38% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.28 | +119.30% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.35 | +274.53% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $27.78 | +79.99% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.67 | +199.40% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.58 | +1,438.72% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $1.13 | +149,336,183.19% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $273.39 | -5.63% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.29 | +3,775.97% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.31 | +1,426.72% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.92 | +468.18% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Dec 5, 2025
Initiates: Sector Outperform
Price Target: $35
Current: $30.32
Upside: +15.44%
Bristol-Myers Squibb Company
Dec 4, 2025
Maintains: Sector Perform
Price Target: $45 → $53
Current: $53.33
Upside: -0.62%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $100.69
Upside: +19.18%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $748.71
Upside: +2.84%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $20.34
Upside: +293.31%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $3.08
Upside: +192.21%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $21.15
Upside: -33.81%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $2.25
Upside: +433.33%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $20.07
Upside: +174.04%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $74.59
Upside: -26.26%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.67
Upside: +461.80%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $96.24
Upside: -48.05%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.68
Upside: +164.08%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $37.90
Upside: -55.15%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $72.14
Upside: -2.96%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $18.55
Upside: +169.54%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $9.82
Upside: +205.50%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $17.18
Upside: +220.14%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.29
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $47.61
Upside: +236.06%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $43.71
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $222.82
Upside: +7.71%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.04
Upside: +79.71%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $208.31
Upside: +3.21%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.10
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.79
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,056.88
Upside: -16.26%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.18
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.18
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.60
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.72
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $220.35
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.70
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.55
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.80
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.88
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.63
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.23
Upside: +1,912.38%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.28
Upside: +119.30%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.35
Upside: +274.53%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $27.78
Upside: +79.99%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.67
Upside: +199.40%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.58
Upside: +1,438.72%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $1.13
Upside: +149,336,183.19%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $273.39
Upside: -5.63%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.29
Upside: +3,775.97%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.31
Upside: +1,426.72%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.92
Upside: +468.18%